EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 PURE Bioscience Reports Fiscal Second Quarter 2026 Financial Results EL CAJON, Calif. - PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2026. Summary of Results - Fiscal Second Quarter Operations Net product sales were $443,000 and $391,000 for the fiscal second quarters ended January 31, 2026 and 2025, respectively. The increase of $52,000 was attributable to increased sales across our end-user network. Net loss for the fiscal second quarter ended January 31, 2026 was $785,000, compared to $798,000 for the fiscal second quarter ended January 31, 2025. During the current quarter, selling, general and administrative expenses decreased by $24,000 due to reductions in board fees and personnel costs. These reductions were offset by increased interest expense related to the Company’s notes payable balance. Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2026, was $727,000, compared to $77…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
PURE Bioscience, Inc.
PUREOTCEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 16, 2026, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal second quarter ended January 31, 2026 and related information. A copy of the press release is attached as Exhibit 99.1.…
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item
2.02. Results of Operations and Financial Condition.
On
March 16, 2026, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal
second quarter ended January 31, 2026 and related information. A copy of the press release is attached as Exhibit 99.1.
The
information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated
by reference into any registration statement or other document filed with the Securities and Exchange Commission.